AstraZeneca shared the topline result from the placebo-controlled ... before AZ and its partner Merck were able to cross the ...

AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...

AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of ...

AstraZeneca has upgraded its revenue and earnings guidance for this year. Total revenues and core earnings per share rose 21% ...

Pascal Soriot, CEO of AstraZeneca, said the growth in total revenue and core earnings per share reflected the "increasing ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Daiichi Sankyo collaboration AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and datopotamab ...

The two parties, together with AstraZeneca, will cooperate on scientific research ... Health Engineering was established ...

AstraZeneca is a company with a turbulent history ... Daiichi apparently declined the offer. Then, in early 2020, more rumours spread that AZ was looking to acquire Gilead, known for its high ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...